Ed Keystone

3.3k citations

25 papers · 572 indexed · h-index 11

Impact in

Rheumatology top 2%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
Hematology top 10%
- Autoimmune and Inflammatory Disorders Research

Papers in ⓘ

Rheumatology 20
- Rheumatoid Arthritis Research and Therapies 19
- Systemic Lupus Erythematosus Research 6
Immunology 7
- Biosimilars and Bioanalytical Methods 4

Co-authors: Carl F. Ware (1 shared paper)Bindee Kuriya (3 shared papers)Joan M. Bathon (2 shared papers)Paul Emery (4 shared papers)Désirée van der Heijde (1 shared paper)Jie Han (1 shared paper)Marc D. Cohen (1 shared paper)E. William St. Clair (1 shared paper)
Journals: Annals of the Rheumatic Diseases (9 papers)The American Journal of the Medical Sciences (1 paper)Therapeutic Advances in Musculoskeletal Disease (1 paper)Lara D. Veeken (1 paper)Cytokine (1 paper)
Partner nations: Canada United States United Kingdom

In The Last Decade

Ed Keystone

25 papers receiving 556 citations

Peers

Countries citing papers authored by Ed Keystone

Since Specialization

Citations

This map shows the geographic impact of Ed Keystone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ed Keystone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ed Keystone more than expected).

Fields of papers citing papers by Ed Keystone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ed Keystone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ed Keystone. The network helps show where Ed Keystone may publish in the future.

Co-authors

The 25 scholars most cited alongside Ed Keystone, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ed Keystone Line = papers co-authored together Ed Keystone links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade Annals of the Rheumatic Diseases ·Josef S Smolen, C. Han, Désirée van der Heijde, Paul Emery, Joan M. Bathon, Ed Keystone, Ravinder N. Maini, Joachim R. Kalden, Daniel Aletaha, Daniel Baker, Jie Han, M Bala, E. William St. Clair	2008	182
2	Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations Arthritis & Rheumatism ·Mark Van Oene, Richard F. Wintle, Xiangdong Liu, Mehrdad Yazdanpanah, Xiangjun Gu, William G. Newman, A Kwan, Benjamin Johnson, Julie Owen, Wenda Greer, Dianne Mosher, Walter P. Maksymowych, Ed Keystone, Laurence A. Rubin, Christopher I. Amos, Katherine Siminovitch	2005	100
3	Tumor Necrosis Factor and Anti-Tumor Necrosis Factor Therapies PubMed ·Ed Keystone, Carl F. Ware	2010	57
4	Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential Therapeutic Advances in Musculoskeletal Disease ·Bindee Kuriya, Marc D. Cohen, Ed Keystone	2017	41
5	The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative Clinical Rheumatology ·Thanu Nadarajah Ruban, Binu Jacob, Janet Pope, Ed Keystone, Claire Bombardier, Bindee Kuriya	2015	30
6	Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort Lara D. Veeken ·Carol Hitchon, Gilles Boire, Boulos Haraoui, Ed Keystone, Janet Pope, Shahin Jamal, D. Tin, Carter Thorne, Vivian P. Bykerk, (unknown)	2016	28
7	The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28 Varies Over Time and by Rheumatoid Factor Status in Early Inflammatory Arthritis (EIA). Results from the CATCH Cohort§ The Open Rheumatology Journal ·Tristan Boyd, A. Bonner, Carter Thorne, Gilles Boire, Carol Hitchon, Boulos Haraoui, Ed Keystone, Vivian P. Bykerk, Janet Pope	2013	17
8	OP0121 Enbrel® (etanercept) vs. methotrexate (mtx) in early rheumatoid arthritis (era trial): two-year follow-up Annals of the Rheumatic Diseases ·M. C. Genovese, RW Martin, Roy Fleischmann, Ed Keystone, Joan M. Bathon, G Spencer-Green, Brian N. Finck	2001	15
9	LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis Annals of the Rheumatic Diseases ·Ed Keystone, Peter C. Taylor, Mark C. Genovese, D. Schlichting, Scott D. Beattie, C. Gaich, R. Fidelus Gort, Monica Luchi, WL Macias	2012	14
10	Clinical Implications of Understanding Radiographic Findings in Relation to Clinical Outcomes in Rheumatoid Arthritis PubMed ·Ed Keystone	2009	12
11	24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Oxford University Research Archive (ORA) (University of Oxford) ·M. C. Genovese, Ed Keystone, P. W. J. Taylor, Edit Drescher, Berclaz P-Y., C H Lee, D. Schlichting, Scott D. Beattie, Rosanne Fidelus-Gort, Monica Luchi, WL Macias	2012	10
12	Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry BMC Rheumatology ·Proton Rahman, P. Baer, Ed Keystone, D. Choquette, Carter Thorne, Boulos Haraoui, Andrew Chow, R. Faraawi, Wojciech P. Olszynski, J. Kelsall, Emmanouil Rampakakis, A.J. Lehman, F. Nantel	2020	10
13	A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study1 Annals of the Rheumatic Diseases ·Peter C. Taylor, Mark C. Genovese, Ed Keystone, Douglas Schlichting, Scott D. Beattie, William L. Macias	2014	10
14	Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis ACR Open Rheumatology ·Bindee Kuriya, Orit Schieir, Marie‐France Valois, Janet Pope, Gilles Boire, Lee Skallerup Bessette, Glen Hazlewood, Carter Thorne, D. Tin, Carol Hitchon, Susan J. Bartlett, Ed Keystone, Vivian P. Bykerk, Lillian Barra, (unknown)	2019	9
15	Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Oxford University Research Archive (ORA) (University of Oxford) ·Charles Peterfy, Paul Emery, M. C. Genovese, Ed Keystone, P. W. J. Taylor, Berclaz P-Y., Julie C. DiCarlo, C H Lee, D. Schlichting, Scott D. Beattie, Monica Luchi, WL Macias	2012	8
16	AB0390 Safety and Efficacy of ABT-494, A Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance To Anti-TNF Biologic Therapy Annals of the Rheumatic Diseases ·Joel M. Kremer, Ed Keystone, Paul Emery, Heidi S. Camp, A. Friedman, Lin Wang, AA Othman, N. Khan, Steven Jungerwirth	2016	7
17	12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis Arthritis & Rheumatism ·Josef S Smolen, D. Schlichting, K.L. Sterling, Ed Keystone, P. W. J. Taylor, M. C. Genovese, Linda K. Johnson, Julia Calzas Rodríguez, C H Lee, C. Gaich	2012	5
18	Infliximab therapy leads to clinical and radiographic benefits in early rheumatoid arthritis patients receiving optimum methotrexate dose Annals of the Rheumatic Diseases ·J. Bathon, Jean‐Pierre Devogelaer, Kalden, M Shiff, Paul Emery, RN Maini, D. van der Heijde, Ed Keystone, D. Baker, Kalpana Patel, Jung-Yong Han, J. Smolen, E. William S.T. Clair	2004	4
19	P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis Journal of Crohn s and Colitis ·R. Besuyen, David Walker, Kevin Winthrop, Mark C. Genovese, Bernard Combe, Yoshiya Tanaka, Alan Kivitz, F. Matzkies, Beatrix Bartók, Lingrun Ye, Ying Guo, Chantal Tasset, John S. Sundy, Ed Keystone, René Westhovens, William F. C. Rigby, G Bürmester	2020	4
20	Assessment of inflammation and damage by MRI in established RA patients with Methotrexate inadequate response receiving Golimumab: Results of the GO-FORWARD trial Annals of the Rheumatic Diseases ·Philip G. Conaghan, P. Emery, Mikkel Østergaard, Ed Keystone, Mark C. Genovese, Lars Klareskog, W. Xu, E. C. Hsia, Mahboob U. Rahman	2011	2

About Ed Keystone

Ed Keystone is a scholar working on Rheumatology, Immunology, Genetics, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 25 papers that have together received 572 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (19 papers), Chronic Lymphocytic Leukemia Research (6 papers), Systemic Lupus Erythematosus Research (6 papers), Autoimmune and Inflammatory Disorders Research (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Lymphoma Diagnosis and Treatment (4 papers), Biosimilars and Bioanalytical Methods (4 papers) and Cytokine Signaling Pathways and Interactions (2 papers). The work is most often cited by research in Rheumatology (365 citations), Hematology (144 citations), Genetics (97 citations), Immunology (147 citations) and Pathology and Forensic Medicine (78 citations). Ed Keystone has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Carl F. Ware, Bindee Kuriya, Joan M. Bathon, Paul Emery, Désirée van der Heijde, Jie Han, Marc D. Cohen, E. William St. Clair, Daniel Baker and Josef S Smolen. Their work appears in journals such as Annals of the Rheumatic Diseases, The American Journal of the Medical Sciences, Therapeutic Advances in Musculoskeletal Disease, Lara D. Veeken and Cytokine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact